MARKETS / NASDAQ / UTMD

NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Utah Medical Products Inc. UTMD

17 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$38.5M

▼ 5.8% YoY

Net income

$11.3M

▼ 18.7% YoY

Free cash flow

$14.3M

▼ 1.9% YoY

In brief

What this company does

UTMD markets a broad range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. Domestically, UTMD's medical devices are sold directly to clinical end-user facilities or designated stocking distributors for medical facilities. UTMD has representation globally in the major developed countries as well as many underdeveloped countries through approximately 200 OUS distributors, 108 of which purchased at least five thousand dollars in UTMD medical devices during 2025. At December 31, 2025, the Company worldwide had 140 full-time employees, 12 part-time employees, 7 regular consultants, 15 independent sales representatives and 9 outside (non-employee) directors of UTMD or its subsidiaries. Almost all of UTMD's internally-manufactured devices are made either in Utah or in Ireland. None of the Company's employees is represented by labor unions or other collective bargaining groups.

Written from the business description in UTAH MEDICAL PRODUCTS INC's annual report to the U.S. Securities and Exchange Commission, filed 27 March 2026. Every sentence was checked against that document before publication.

Growth

USD 38.5M

Revenue, FY2025 · full 17-year series below

Revenue $M Net income $M

FY2025 · Revenue 38.5 · Net income 11.3

Compound annual growth

Revenue

−9.7%

−1.8%

−0.4%

+2.9%

Net income

−11.8%

+0.9%

−0.5%

+4.3%

EPS, diluted

−8.3%

+3.4%

Returned to shareholders

+31.0%

+2.8%

+12.4%

+4.9%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at −1.8% a year over five years — but profit grew faster: net income at +0.9%, earnings per share at +3.4%.

The share count fell from 0.00B to 0.00B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

29 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 29.6% · Net 29.3%

ROE

FY2025 · ROE 9.5%

Gross margin57.1%

Operating margin29.6%

Net margin29.3%

Return on assets9.2%

EBITDAUSD 12.2M

Each USD of equity produced 10 cents of profit this year.

Cash & shareholders

USD 12.3M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 14.3

Net buybacks $M Dividends $M

FY2025 · Dividends 4.0 · Net buybacks 8.4

Dividends paidUSD 4.0M

Net buybacksUSD 8.4M

Share of profit109.3%

Consecutive raises—

USD 4.0M in dividends and USD 8.4M in buybacks — 109% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 122.5M

EquityUSD 119.3M

CashUSD 85.8M

Gross debtUSD 0.00

Net debtUSD -85.8M

Current ratio37.62×

The company holds more cash than debt.

The 17-year record

17 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue $B	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Operating income $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income tax $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Free cash flow $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EPS, diluted $	3.48	3.96	4.57	4.52	4.04	2.94	3.94	4.95	2.28	3.22	3.14	3.02	3.02	2.74	2.03	1.65	1.72
Dividend / sh $	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Payout %	35	31	26	19	78	38	28	22	35	32	32	33	32	35	46	100	53
ROE %	9.5	11.3	13.7	14.9	14.1	10.6	15.5	22.2	11.5	17.5	17.6	18.2	20.4	22.2	18.9	15.9	·
Shares out B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 82 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 13 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivitySurgical & Medical Instruments & Apparatus

Listed onNASDAQ

Incorporated inUtah

Fiscal year endsDecember 31

SEC categorysmaller reporting company

Data on record since2009